Lipocine Inc. Files 8-K Report
Ticker: LPCN · Form: 8-K · Filed: 2026-04-02T09:35:13-04:00
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
Related Tickers: LPCN
TL;DR
Lipocine filed an 8-K, check for updates.
AI Summary
On April 2, 2026, Lipocine Inc. filed an 8-K report detailing other events and financial statements. The filing includes exhibits such as the 8-K form itself and supplementary materials. No specific financial figures or material events were detailed in the provided filing information.
Why It Matters
This filing indicates Lipocine Inc. is providing updates or disclosures to the SEC, which could contain important information for investors regarding the company's status or recent developments.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report with no immediate indication of significant negative or positive events.
Key Players & Entities
- Lipocine Inc. (company) — Filer of the 8-K report
- 0001535955 (company) — CIK number for Lipocine Inc.
- 0001493152-26-014834 (other) — SEC Accession Number for the filing
- 2026-04-02 (date) — Filing Date and Period of Report
FAQ
What specific events are detailed in Item 8.01 of the 8-K filing?
The provided filing information lists Item 8.01 as 'Other Events' but does not specify the nature of these events.
What is the purpose of Item 9.01 in this 8-K filing?
Item 9.01 pertains to 'Financial Statements and Exhibits', indicating that financial information and supporting documents are included.
When was this 8-K filing accepted by the SEC?
The filing was accepted on April 2, 2026, at 09:35:13.
What is the CIK number for Lipocine Inc.?
The CIK number for Lipocine Inc. is 0001535955.
Where is Lipocine Inc. located based on the mailing address provided?
Lipocine Inc.'s mailing address is 675 Arapaen Drive, Suite 202, Salt Lake City, UT 84108.
From the Filing
EDGAR Filing Documents for 0001493152-26-014834 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001493152-26-014834 Filing Date 2026-04-02 Accepted 2026-04-02 09:35:13 Documents 13 Period of Report 2026-04-02 Items Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K form8-k.htm iXBRL 8-K 41920 2 EX-99.1 ex99-1.htm EX-99.1 36588 3 GRAPHIC form8-k_001.jpg GRAPHIC 6119 Complete submission text file 0001493152-26-014834.txt 267180 Data Files Seq Description Document Type Size 4 XBRL SCHEMA FILE lpcn-20260402.xsd EX-101.SCH 3014 5 XBRL LABEL FILE lpcn-20260402_lab.xml EX-101.LAB 34239 6 XBRL PRESENTATION FILE lpcn-20260402_pre.xml EX-101.PRE 22358 18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3209 Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383 Lipocine Inc. (Filer) CIK : 0001535955 (see all company filings) EIN. : 990370688 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-36357 | Film No.: 26831012 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)